Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Rhea-AI Summary

Oruka Therapeutics (Nasdaq: ORKA) announced participation and presentations at multiple investor conferences in February–March 2026, including Guggenheim Emerging Outlook, TD Cowen, UBS Biotech Summit Miami, Jefferies Biotech on the Beach, Leerink Global Healthcare, and Barclays Global Healthcare.

Presentation dates and times are listed; a webcast and replay will be available on the Oruka investor events website.

Argus Feb 9 session

+0.64% close to close Open Argus

Details

News Market Reaction – ORKA

On Feb 9, the day this news came out, ORKA closed 0.64% above the previous close.

Data tracked by StockTitan Argus for the Feb 9 session.

Key Figures

ORKA-002 half-life: 75–80 days Phase 1 sample size: 24 patients Planned Phase 2 size: ~160 patients +5 more

ORKA-002 half-life

75–80 days

Phase 1 interim data reported Jan 12, 2026

Phase 1 sample size

24 patients

ORKA-002 Phase 1 trial

Planned Phase 2 size

~160 patients

Planned ORCA-SURGE Phase 2 psoriasis trial in 1H 2026

Cash & securities

$500.9M

As of Sept 30, 2025 (Q3 2025 results)

Resale registered shares

39,425,806 shares

Amended resale registration statement (S-3/A) filed Oct 14, 2025

Shares outstanding

48,384,150 shares

As of Sept 19, 2025 in resale filing

Resale as % of outstanding

59%

Resale Shares vs outstanding, assuming warrant exercises and conversions

Vanguard ownership

2,453,530 shares (5.06%)

Schedule 13G as of Dec 31, 2025

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Clinical data update

   24h Move

   +10.2%

   Positive interim Phase 1 data for ORKA-002 and trial plans for ORKA-001.

2. Jan 06

   Conference participation

   24h Move

   -1.0%

   Announcement of presentation at the 44th Annual J.P. Morgan Healthcare Conference.

3. Dec 11

   Board/management change

   24h Move

   -0.1%

   New board member with significant commercial experience and related board transition.

4. Nov 12

   Earnings and update

   24h Move

   +0.3%

   Q3 2025 results with strong cash position and progression of ORKA-001/002 programs.

5. Oct 29

   Conference participation

   24h Move

   +0.6%

   Multiple November investor conference presentations on chronic skin disease biologics.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

biologics, plaque psoriasis

2 terms

biologics medical

"a clinical-stage biotechnology company developing novel biologics designed to set a new"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

plaque psoriasis medical

"treatment of chronic skin diseases including plaque psoriasis, today announced its"

A chronic autoimmune skin condition that causes raised, red, scaly patches where the skin sheds too quickly, like a tree producing bark in clumps instead of renewing smoothly. It matters to investors because prevalence, severity, and treatment options drive demand for therapies, shape clinical trial design and regulatory review, and affect potential market size, pricing and reimbursement for drugs or devices aimed at relieving symptoms or altering the underlying immune response.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its participation and presentation at multiple upcoming conferences:

Guggenheim Emerging Outlook: Biotech Summit 2026
Date: Thursday, February 12^th, 2026
Presentation Time: 10:30AM ET

TD Cowen 46^th Annual Health Care Conference
Date: Tuesday, March 3^rd, 2026
Presentation Time: 1:10PM ET

UBS Biotech Summit Miami
Date: Monday March 9^th, 2026

Jefferies Biotech on the Beach Summit
Date: March 10^th, 2026

Leerink Global Healthcare Conference
Date: March 11^th, 2026
Presentation Time: 1:00PM ET

Barclays 28^th Annual Global Healthcare Conference
Date: March 12^th, 2026
Presentation Time: 10:30AM ET

A webcast and replay of Oruka’s presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.

About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.

Investor Contact: 
Alan Lada 
(650)-606-7911 
alan.lada@orukatx.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Oruka (ORKA) presenting at the Guggenheim Emerging Outlook: Biotech Summit?

Oruka will present at Guggenheim on February 12, 2026 at 10:30AM ET. According to Oruka, the presentation is part of a series of investor events and a webcast plus replay will be available on the company's investor events website for later viewing.

What are the dates and times for Oruka's (ORKA) TD Cowen and Barclays presentations?

Oruka is scheduled at TD Cowen on March 3, 2026 at 1:10PM ET and Barclays on March 12, 2026 at 10:30AM ET. According to Oruka, both presentations will be webcast with replays accessible on the investor events site.

Will Oruka (ORKA) webcast its presentations from the March 2026 conference roadshow?

Yes, Oruka will webcast its conference presentations and provide replays online. According to Oruka, investors can access live webcasts and archived replays via the company's investor events and presentations webpage.

Which Miami conference will Oruka (ORKA) attend in March 2026 and when?

Oruka will attend the UBS Biotech Summit Miami on March 9, 2026 and Jefferies Biotech on the Beach on March 10, 2026. According to Oruka, dates reflect its planned investor engagement schedule with webcasts available when provided.

Where can investors find Oruka's (ORKA) presentation replays and event details?

Investors can find presentation replays and event details on Oruka's investor events website. According to Oruka, the company will post live webcasts and archived replay links on its investor relations events and presentations page.

What is the purpose of Oruka's (ORKA) multiple conference presentations in Feb–Mar 2026?

The presentations are intended to update investors on Oruka's clinical-stage programs and corporate progress. According to Oruka, these meetings provide opportunities for investor Q&A and broader visibility via live webcasts and replay availability.